• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market

    1/7/25 6:30:00 AM ET
    $ZOM
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $ZOM alert in real time by email

    License Agreement Expands Zomedica's Portfolio with Revolutionary Hemostatic Technology

    ANN ARBOR, MI / ACCESSWIRE / January 7, 2025 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that it had entered into a license and supply agreement with Cresilon, Inc. to market and sell the Vetigel® hemostatic gel product line on an exclusive basis in the United States and on a non-exclusive basis outside the United States.

    Under the terms of the agreement, Zomedica will assume responsibility for supplying U.S. customers and will collaborate with Cresilon to support customers outside the U.S. This partnership enables Zomedica to further its mission of delivering innovative solutions that enhance patient care and operational efficiency for veterinary practitioners.

    Vetigel is a groundbreaking, plant-based formula designed to stop bleeding rapidly when applied directly to the source. Unlike traditional methods, Vetigel halts bleeding in seconds without becoming incorporated into the clot. The product has been validated in clinical studies reported in white papers, demonstrating its ability to save time during surgical procedures and significantly reduce blood loss in patients. Key applications include:

    • Surgical Procedures: Effective in controlling bleeding during soft organ biopsies and excisions;

    • Dental Applications: Successfully used to manage bleeding in routine and advanced dental procedures;

    • Emergency Care: Proven efficacy in treating venous and arterial bleeds; and

    • Liver Biopsy: Demonstrated to stop bleeding faster than competitive hemostatic agents.

    "We are excited to add Vetigel® to Zomedica's portfolio of innovative veterinary products," said Kevin Klass, Senior Vice President of Sales at Zomedica. "Vetigel's ability to rapidly stop bleeding across a variety of procedures makes it an invaluable tool for veterinarians, enabling them to enhance patient outcomes while improving surgical efficiency. This partnership with Cresilon allows us to bring cutting-edge solutions to veterinary professionals in the U.S. and beyond."

    Greg Blair, Zomedica's Senior Vice President, Business Development & Strategic Planning, added, "This new venture with Cresilon is another way Zomedica stays true to our mission of enhancing the quality of care for pets, increasing pet parent satisfaction, and improving the workflow, cash flow, and profitability of veterinary practices. By bringing innovative solutions like Vetigel to market, we are empowering veterinarians to deliver better outcomes and experiences for their patients and clients."

    "This partnership with Zomedica is ideal for the future of Vetigel," said Joe Landolina, CEO of Cresilon. "Zomedica's established reputation, robust field sales team, and commitment to veterinary excellence make them the perfect match for expanding the reach of this revolutionary product. Together, we look forward to making Vetigel an essential tool for veterinary practices worldwide."

    Vetigel's versatility and proven efficacy make it a game-changer for veterinary practices, addressing critical needs in both routine and emergency settings. Zomedica looks forward to expanding access to this exciting technology to more customers leveraging our existing field sales team, frequent trade show programs, and weekly continuing education programs.

    For more information about Vetigel hemostatic gel, please visit https://zomedica.com/vetigel.

    About Zomedica
    Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. An NYSE American company, Zomedica grew revenue 33% in 2023 to $25 million and maintains a strong balance sheet with approximately $78 million in liquidity as of September 30, 2024. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information about Zomedica and our full range of products visit www.zomedica.com.

    About Cresilon
    Cresilon® is a Brooklyn-based biotechnology company that develops, manufactures, and markets hemostatic medical devices utilizing the company's proprietary hydrogel technology. The company's plant-based technology has revolutionized the current standard by stopping bleeding in seconds. The company's current and future product lines target trauma care, biosurgery, and animal health. Cresilon's mission is to save lives. For more information about Cresilon, which was named to Fast Company's annual list of the World's Most Innovative Companies of 2024, ranking No. 1 in the medical devices category, visit www.cresilon.com.

    Follow Zomedica

    • Email Alerts: http://investors.zomedica.com

    • LinkedIn: https://www.linkedin.com/company/zomedica

    • Facebook: https://m.facebook.com/zomedica

    • X (formerly Twitter): https://twitter.com/zomedica

    • Instagram: https://www.instagram.com/zomedica_inc

    Cautionary Note Regarding Forward-Looking Statements
    Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

    Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.

    Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to Cresilon's ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products, including acceptance of the Vetigel® hemostatic gel line; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including meeting distribution obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

    The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

    Investor Relations Contact:
    Zomedica Investor Relations
    [email protected]
    1-734-369-2555

    SOURCE: Zomedica Corp.



    View the original press release on accesswire.com

    Get the next $ZOM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZOM

    DatePrice TargetRatingAnalyst
    1/6/2023$6.00Buy
    Dawson James
    More analyst ratings

    $ZOM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market

      License Agreement Expands Zomedica's Portfolio with Revolutionary Hemostatic Technology ANN ARBOR, MI / ACCESSWIRE / January 7, 2025 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that it had entered into a license and supply agreement with Cresilon, Inc. to market and sell the Vetigel® hemostatic gel product line on an exclusive basis in the United States and on a non-exclusive basis outside the United States.Under the terms of the agreement, Zomedica will assume responsibility for supplying U.S. customers and will collaborate with Cresilon to

      1/7/25 6:30:00 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone

      With the addition of these two new assay launches, Zomedica has added 8 new assays in the past 18 months to the rapidly growing TRUFORMA Platform ANN ARBOR, MI / ACCESSWIRE / December 23, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of two new canine assays for the TRUFORMA In-Clinic Biosensor Testing Platform.Zomedica's canine NT-poBNP test is used for the quantitative detection of NT-proBNP in canine EDTA plasma or serum. Elevated NT-proBNP can be indicative of conditions such as congestive heart failure, assisting in the di

      12/23/24 6:30:00 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer

      Seasoned executive brings a broad skill set to Zomedica's leadership team ANN ARBOR, MI / ACCESSWIRE / December 19, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Scott A. Jordan as its Executive Vice President, Finance and Chief Financial Officer, effective January 1, 2025."Scott brings a broad range of skills and experience that will be increasingly important to us as we move forward," said Larry Heaton, Zomedica's Chief Executive Officer. We are excited to welcome him to the Zomedica team and look forward to leveraging his expertis

      12/19/24 6:30:00 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care

    $ZOM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed

      SC 13G/A - Zomedica Corp. (0001684144) (Subject)

      2/16/21 8:01:32 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care

    $ZOM
    Financials

    Live finance-specific insights

    See more
    • Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth

      ANN ARBOR, MI / ACCESSWIRE / November 7, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the third quarter ended September 30, 2024."We are very pleased with our performance, highlighted by record third quarter revenue and a double-digit increase compared to last year, which demonstrates that the execution of our growth initiatives has continued to pay dividends. As expected, PulseVet® capital sales rebounded during the third quarter bolstered by a full-strength sales team in the U.S. and continued positive

      11/7/24 4:25:00 PM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Zomedica to Report Third Quarter 2024 Financial Results and Provide Business Update on November 7th at 4:30 p.m. ET

      ANN ARBOR, MI / ACCESSWIRE / October 23, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Thursday, November 7, 2024, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its thirdquarter ended September 30, 2024. A question-and-answer session will follow management's prepared remarks.Event: Zomedica Corp. Q3 2024 Financial Results Conference CallDate: Thursday, November 7, 2024Time: 4:30 p.m. Eastern TimeLive Call: +1-800-717-1738 (U.S. Toll-Free) or +1-646-307-1865 (Internat

      10/23/24 3:00:00 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Zomedica Announces Second Quarter 2024 Financial Results: Revenue of $6.1 Million; 71% Gross Margin, and $83.0 Million in Liquidity to Support Growth

      Diagnostic revenues up 68% year-over-year ANN ARBOR, MI / ACCESSWIRE / August 14, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the second quarter ended June 30, 2024."We are pleased with the progress in the quarter, which represents the highest second quarter for the Company to date. We saw significant growth in our diagnostic product revenue, reflecting growing adoption of our TRUFORMA® and VETGuardian® products. We also enjoyed substantial growth in consumable products, reflecting the robust usage of ou

      8/14/24 4:05:00 PM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care

    $ZOM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Rowe Jeffrey M bought $96,098 worth of shares (1,439,005 units at $0.07) (SEC Form 4)

      4/A - Zomedica Corp. (0001684144) (Issuer)

      3/27/25 9:56:49 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Director Williams Rodney James bought $6,900 worth of shares (100,000 units at $0.07), increasing direct ownership by 62% to 261,900 units (SEC Form 4)

      4 - Zomedica Corp. (0001684144) (Issuer)

      3/20/25 9:52:31 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Chief Financial Officer Jordan Scott bought $18,600 worth of shares (300,000 units at $0.06) (SEC Form 4)

      4 - Zomedica Corp. (0001684144) (Issuer)

      3/19/25 11:47:14 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care

    $ZOM
    Leadership Updates

    Live Leadership Updates

    See more
    • Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer

      Seasoned executive brings a broad skill set to Zomedica's leadership team ANN ARBOR, MI / ACCESSWIRE / December 19, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Scott A. Jordan as its Executive Vice President, Finance and Chief Financial Officer, effective January 1, 2025."Scott brings a broad range of skills and experience that will be increasingly important to us as we move forward," said Larry Heaton, Zomedica's Chief Executive Officer. We are excited to welcome him to the Zomedica team and look forward to leveraging his expertis

      12/19/24 6:30:00 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Zomedica Appoints New Chief Financial Officer

      ANN ARBOR, MI / ACCESSWIRE / March 17, 2023 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Peter L. Donato as its Chief Financial Officer, effective March 16, 2023. Mr. Donato brings over 30 years of public and private company experience in a wide range of finance and business functions primarily in the human health sector, having held a number of senior positions from CFO, President and CEO, Executive Vice President, Senior Vice President, Vice President and Controller. Prior to joining Zomedica, Mr. Donato had a successful consulting

      3/17/23 6:30:00 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Zomedica Appoints Dr. Pamela Nichols, DVM to Board of Directors

      ANN ARBOR, MI / ACCESSWIRE / August 23, 2022 / Zomedica Corp. (NYSE:ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced that Pamela Nichols, DVM has been appointed to its Board of Directors and is joining the Audit and Governance committees.Dr. Nichols is the founder of six successful veterinary hospitals and dog boarding/daycare facilities. Her newest hospital is Animal Care Daybreak in South Jordan Utah, which opened in October of 2019. She earned her doctorate in veterinary medicine at Colorado State University in 1996 and her Canine Rehabilitation Practitioner (CCRP) certification in 2004. She

      8/23/22 6:30:00 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care

    $ZOM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Rowe Jeffrey M bought $96,098 worth of shares (1,439,005 units at $0.07) (SEC Form 4)

      4/A - Zomedica Corp. (0001684144) (Issuer)

      3/27/25 9:56:49 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Director Williams Rodney James bought $6,900 worth of shares (100,000 units at $0.07), increasing direct ownership by 62% to 261,900 units (SEC Form 4)

      4 - Zomedica Corp. (0001684144) (Issuer)

      3/20/25 9:52:31 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Chief Financial Officer Jordan Scott bought $18,600 worth of shares (300,000 units at $0.06) (SEC Form 4)

      4 - Zomedica Corp. (0001684144) (Issuer)

      3/19/25 11:47:14 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care

    $ZOM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dawson James initiated coverage on Zomedica Pharmaceuticals with a new price target

      Dawson James initiated coverage of Zomedica Pharmaceuticals with a rating of Buy and set a new price target of $6.00

      1/6/23 9:00:39 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care

    $ZOM
    SEC Filings

    See more
    • Zomedica Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Zomedica Corp. (0001684144) (Filer)

      3/13/25 6:59:46 PM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 10-K filed by Zomedica Corp.

      10-K - Zomedica Corp. (0001684144) (Filer)

      3/13/25 4:03:40 PM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 25-NSE filed by Zomedica Corp.

      25-NSE - Zomedica Corp. (0001684144) (Subject)

      3/13/25 12:02:46 PM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care